Table 4.

Adverse events according to each treatment group, n

Adverse events	Group A* (n = 100)	Group B* (n = 100)	Group C* (n = 100)	Group D*,† (n = 99)	P
Death	0	0	0	0	1.000
Patient withdrew due to adverse events	1	1	2	3	0.663
Any adverse event	4	7	4	9	0.353
Any serious adverse event‡	0	0	0	0	1.000
Abnormal liver function	0	3	1	3	0.267
Hypotension	0	1	2	0	0.298
Hyperkalemia	1	2	1	0	0.571
Neutropenia	1	0	0	2	0.292
Rash	0	0	0	2	0.107
Skin purpura	0	0	0	1	0.386
Upper gastrointestinal bleeding	0	0	0	1	0.386
Herpes zoster	1	0	0	0	0.392
Urinary tract infection	0	1	0	0	0.392
Upper respiratory tract infection	1	0	0	0	0.392

*Group A: Telmisartan 80 mg/d + placebo, Group B: Telmisartan 80 mg/d + 50 mg/d clopidogrel, Group C: Telmisartan 80 mg/d + 20 mg/d leflunomide, Group D: Telmisartan 80 mg/d + 50 mg/d clopidogrel + 20 mg/d leflunomide; ^†One patient did not receive the allocated intervention and was not included in the primary analysis; ^‡Severe adverse events refer to adverse events that cause initial or prolonged hospitalization, handicaps, employment handicaps, congenital malformation, life-threatening health events, or death.